Using AI algorithms to diagnose and assess coronary artery disease for intervention is about to become more mainstream after medtech giant, Medtronic, agreed to exercise its acquisition rights on AI FFR specialist, CathWorks, for $585M up-front.
- Although effective, traditional wire-based FFR measurement is invasive, requires more time, more radiation exposure, and higher costs, limiting its adoption.
- CathWorks’ FFRangio technology solves this problem by using algorithms to obtain FFR measurements across the coronary artery tree from standard angiograms.
Until now CathWorks’ FFRangio has only been available in the U.S., Europe, and Japan through Medtronic’s distribution network, but this expansion will take the tech global, with Medtronic’s full backing.
This strategic acquisition stems from Medtronic’s staged investment in CathWorks, which started with a $75M minority stake in 2022 and is now part of the company’s broader plan to expand its presence in the cath lab.
- Medtronic entered the stent business in 1998 with its acquisition of Arterial Vascular Engineering for about $3.7B.
- Since then, the company has improved and developed its own internal stent tech, with the Resolute Onyx and newer Onyx Frontier drug eluting stents.
- These products are engineered for treating coronary artery disease via PCI and go hand-in-hand with CathWorks’ diagnostic system.
The move is reminiscent of Philips’ SpectraWAVE acquisition in December 2025, which saw a similar on-boarding of wire-free FFR tech, signaling that the big players see the value in non-invasive CAD evaluation and planning.
- That acquisition stemmed from Philip’s cath lab focused expansion, though its approach is more imaging centered than interventional.
- Meanwhile, with Medtronic’s stent portfolio, integrating FFRangio could accelerate the technology’s adoption through established customers.
Medtronic might have also already laid the groundwork for two potentially similar acquisitions with its recent investing agreements, both in the interventional cardiology space.
- One is an exclusive U.S. distribution agreement with Contego Medical in January 2025, which started with increased investment ($22.3M) and comes with acquisition rights.
- The other is Medtronic’s $90M investment in Anteris Technologies (16% stake), though Medtronic can’t increase this stake till May 2027.
The Takeaway
Medtronic has consistently shown a “try-before-you-buy” approach when it comes to expanding its cardiology portfolio, and its latest purchase of CathWorks is no different. That’s a strategy that kept Medtronic safe while giving CathWorks’ FFRangio the room to grow into a global technology that could redefine PCI planning.
